key: cord-0863254-2oth6yxf
authors: Masset, Christophe; Kervella, Delphine; Kandel-Aznar, Christine; Fantou, Aurélie; Blancho, Gilles; Hamidou, Mohamed
title: Relapse of IgG4 related nephritis following mRNA Covid vaccine
date: 2021-06-09
journal: Kidney Int
DOI: 10.1016/j.kint.2021.06.002
sha: 3e650e17bb80b0563c8ecc11ce88828c8f4b540c
doc_id: 863254
cord_uid: 2oth6yxf

nan

presented with intense asthenia with arthralgias and myalgias. SCr was elevated at 210µmol/l on the 5 th of March 2021, increased to 250µmol/l on the 22 th of March 2021 and was associated with recurrence of aseptic leukocyturia. Anti SSA-52 levels increased from 4 UI/l to 17 UI/l. SARS-Cov 2 serology was positive for anti-spike protein at 177 UI/l (electrochemiluminescence immunoassay by Roche Elecsys ® ).

Steroid therapy was initiated at 0.5mg/kg associated with Rituximab perfusion (500mg) allowing a quick improvement of the general symptoms and resolution of AKI. Anti SSA-52 levels also decreased to 12UI/l by May 2021 (Figure 2 ).

Our report highlights the possibility of immune disease relapse following mRNA vaccine, a situation previously described by others. It is currently unknown if immune disease recurrence is linked to direct immune activation following vaccination or to chronic immune activation following a paucisymptomatic allergic reactionor both.

Indeed, IgG4-RD pathogenesis has been linked to IgE production, as seen in late immune mediated allergic reactions 4 

Minimal Change Disease relapse following SARS-CoV2 mRNA vaccine

Relapse of Primary Membranous Nephropathy after inactivated SARS-CoV-2 Virus Vaccination

Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients

IgG4-related disease: an update on pathophysiology and implications for clinical care